Literature DB >> 35418240

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association.

P Barton Duell, Francine K Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E Cohen, Jay D Horton, Gregg S Pressman, Peter P Toth.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition. Hepatic complications from NAFLD include nonalcoholic steatohepatitis, hepatic cirrhosis, and hepatocellular carcinoma. In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD. Accordingly, the purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.

Entities:  

Keywords:  AHA Scientific Statements; cardiovascular diseases; diabetes mellitus; hepatocytes; hypertriglyceridemia; insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; triglycerides

Mesh:

Year:  2022        PMID: 35418240     DOI: 10.1161/ATV.0000000000000153

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Detangling the interrelations between MAFLD, insulin resistance, and key hormones.

Authors:  Shreya C Pal; Mohammed Eslam; Nahum Mendez-Sanchez
Journal:  Hormones (Athens)       Date:  2022-08-03       Impact factor: 3.419

Review 2.  Ectopic Fat and Cardiac Health in People with HIV: Serious as a Heart Attack.

Authors:  Ana N Hyatt; Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2022-08-13       Impact factor: 5.495

3.  Fatty liver index and cardiovascular outcomes in never-treated hypertensive patients: a prospective cohort.

Authors:  Eirini Siafi; Ioannis Andrikou; Costas Thomopoulos; Dimitrios Konstantinidis; Niki Kakouri; Fotis Tatakis; Maria Kariori; Christina Filippou; Ioannis Zamanis; Eleni Manta; Sotirios Drogkaris; Ioannis Liatakis; Dimitrios Polyzos; Costas Tsioufis
Journal:  Hypertens Res       Date:  2022-10-14       Impact factor: 5.528

4.  A retrospective study on the relationship between fibrosis‑4 index and all‑cause mortality in patients with acute myocardial infarction.

Authors:  Maolin Cao; Tingming Li; Zhifeng Li; Fang Gong; Zijun Chen
Journal:  Exp Ther Med       Date:  2022-08-31       Impact factor: 2.751

5.  Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Authors:  Qian Jin; Rui-Xu Yang; Jian-Gao Fan
Journal:  Clin Mol Hepatol       Date:  2022-06-22

Review 6.  Glycation and a Spark of ALEs (Advanced Lipoxidation End Products) - Igniting RAGE/Diaphanous-1 and Cardiometabolic Disease.

Authors:  Lakshmi Arivazhagan; Raquel López-Díez; Alexander Shekhtman; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Front Cardiovasc Med       Date:  2022-06-24

Review 7.  New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis.

Authors:  Georgiana-Diana Cazac; Cristina-Mihaela Lăcătușu; Cătălina Mihai; Elena-Daniela Grigorescu; Alina Onofriescu; Bogdan-Mircea Mihai
Journal:  Life (Basel)       Date:  2022-08-04

8.  Cardiovascular disease risk stratification in type 2 diabetes.

Authors:  Harriet Esdaile; Jamil Mayet; Neil Hill
Journal:  Diabet Med       Date:  2022-08-04       Impact factor: 4.213

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.